Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 16, 2012

View Archived Issues

Advanced Cancer Therapeutics receives NIH grant to develop novel agent for brain cancer

Specialised Therapeutics Australia in-licenses rights to anamorelin

Probiodrug discloses novel glutaminyl cyclase inhibitors

Chinese researchers disclose new PAF acetylhydrolase inhibitors

Eternity Bioscience patents novel PARP-1 inhibitors

Teijin Pharma presents novel CaSR antagonists with promising in vivo activity

NKTR-171 demonstrates efficacy in animal models of neuropathic pain

Grindeks discloses single enantiomer for cognitive disorders

Eli Lilly reports phase III data for ramucirumab in gastric cancer

New CCR2 receptor antagonists presented by Merck & Co.

Octahydrogenacridine succinate shows promising pharmacokinetics in healthy Chinese subjects

Idera Pharmaceuticals completes patient enrollment in phase II IMO-3100 trial

Researchers at Reata Pharmaceuticals prepare new NO production inhibitors

FDA accepts Serada NDA for filing

FDA grants Meridian Laboratories pre-IND meeting for ML-061

Tasimelteon restores cortisol rhythms in blind patients

Enrollment of fifth patient in ibrutinib trial triggers milestone payment

Novavax begins phase I trial of RSV vaccine candidate in older subjects

Endoribonuclease Dicer may be a marker for multiple sclerosis

Novo Nordisk submits U.S. and E.U. applications for turoctocog alfa

BioDelivery Sciences will launch Breakyl in the E.U.

FDA approves expanded indication for Actemra

Onyx Pharmaceuticals completes enrollment in phase III FOCUS trial

Abbott discloses initial results from phase IIb study of interferon-free HCV treatment regimen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 7, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.